Last reviewed · How we verify
Tipranavir/Ritonavir
Tipranavir/Ritonavir is a protease inhibitor used in combination with other medications to treat HIV-1 infection.
Tipranavir/Ritonavir is a protease inhibitor used in combination with other medications to treat HIV-1 infection. Used for Treatment of HIV-1 infection in adults and children, Treatment of HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | Tipranavir/Ritonavir |
|---|---|
| Also known as | Aptivus |
| Sponsor | Johns Hopkins University |
| Drug class | Protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Tipranavir works by inhibiting the protease enzyme, which is essential for the replication of the HIV-1 virus. This action prevents the virus from producing new viral particles, thereby reducing the viral load in the body.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency (PHASE1)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients (PHASE2)
- 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study (PHASE2)
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |